Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
AssigneeNymox Corporation
InventorPaul Averback
Life of this patent
Estimating the term…
Abstract
The embodiments include methods of treating conditions requiring removal or destruction of cellular elements, such as benign or malignant tumors using compounds based on small peptides in combination with additional active agent(s). The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a mammal in need thereof. Carrying out the method unexpectedly reduces the need for subsequent invasive surgical intervention.
Claims6
A method of reducing the need for subsequent invasive surgical intervention in treatment naïve humans having benign prostatic hyperplasia (BPH) who had not previously taken an additional active agent for BPH, comprising:
- (a) selecting treatment naïve humans having BPH who had not previously taken an additional active agent;
- and (b) administering to the treatment naïve human about 2.5 mg of an isolated peptide consisting of the amino acid sequence in SEQ ID NO. 66 (Ile-Asp-Gln-Gln-Val-Leu-Ser-Arg-Ile-Lys-Leu-Gludle-Lys-Arg-Cys-Leu) to reduce invasive surgical procedures within 2 years from administration by an amount within the range of from about 75 to 95%, when compared to treatment naïve humans having BPH receiving a placebo.
A method of reducing the need for subsequent invasive surgical intervention in humans having benign prostatic hyperplasia (BPH) comprising:
- (a) administering to the human an isolated peptide consisting of the amino acid sequence in SEQ ID NO. 66 (Ile-Asp-Gln-Gln-Val-Leu-Ser-Arg-Ile-Lys-Leu-Gludle-Lys-Arg-Cys-Leu);
- and (b) administering to the human about 2.5 mg of the isolated peptide a second time at about 1 to 2 years after the administration in (a) to reduce invasive surgical procedures within 2 years from administration in (a), by an amount within the range of from about 45% to about 100%, when compared to humans having BPH receiving the peptide only once.
A method of reducing the need for subsequent invasive surgical intervention in treatment naïve humans having benign prostatic hyperplasia (BPH) who had not previously taken an additional active agent for BPH comprising:
- (a) selecting treatment naïve humans having BPH who had not previously taken an additional active agent;
- and (b) administering to the treatment naïve human about 2.5 mg of an isolated peptide consisting of the amino acid sequence in SEQ ID NO. 66 (Ile-Asp-Gln-Gln-Val-Leu-Ser-Arg-Ile-Lys-Leu-Gludle-Lys-Arg-Cys-Leu) to reduce invasive surgical procedures within 2 years from administration by an amount within the range of from about 85% to about 90%, when compared to treatment failure humans having BPH to whom the isolated peptide was administered.
Dependencies are inferred from the claim text.